Background: The U.S. population is aging with an increasing burden of Parkinson's disease (PD) and its frequent co‐occurring mental health disorders. However, mortality trends related to PD and these comorbid mental health disorders among older adults remain understudied. Objective: To examine trends in mortality due to PD and related mental health conditions among adults aged 45 and older in the United States from 1999 to 2023. Methods: We extracted mortality data for PD and mental health‐related conditions among individuals aged 45 and older from the CDC WONDER database. Age‐adjusted mortality rates (AAMRs) were calculated per 100,000 persons and stratified by sex, race/ethnicity, census region, and urbanization status. Annual percentage changes (APCs) with their 95% confidence intervals (CIs) were estimated using the Joinpoint regression program. Results: PD and its associated mental health disorders resulted in 238,378 deaths between 1999 and 2023. The AAMR increased significantly from 3.83 in 1999 to 8.49 in 2023 with an AAPC of 3.20 ( p = 0.005). Males consistently showed higher AAMRs than females (overall AAMR male: 11.40 vs. female: 5.75). Non‐Hispanic (NH) Whites had the highest mortality rates (8.67), while NH African Americans exhibited the lowest (4.66). Crude mortality rate was the highest among older adults (21.09), reflecting the greatest burden in this population. Similarly, the mortality rates were higher in nonmetropolitan areas (8.15) than the metropolitan areas (7.72). The highest AAMR was noted in the Midwest (9.18), with a standard deviation of 14.08 in Minnesota and 5.44 in Arizona. The majority of the deaths were recorded in nursing or long‐term care facilities (52.65%). Conclusion: The increasing trend in mortality highlights the necessity of focused preventive, diagnostic, and treatment approaches for all susceptible groups.

Purpose: Glioblastoma (GBM) remains the most common and lethal primary central nervous system tumor, with a median survival of only 14.6 months under standard care. The tumor’s characteristic "Warburg effect"—a dependency on aerobic glycolysis for energy—creates a metabolic vulnerability. This review evaluates the efficacy and safety of the ketogenic diet (KD) as an adjunctive metabolic therapy aimed at exploiting this glucose dependency. Methods: This PRISMA-compliant systematic review updates clinical evidence by synthesizing data from databases from 2000 to September 2025. We searched PubMed, Embase, Cochrane, and Web of science for human studies assessing the ketogenic diet (KD) in glioblastoma and high-grade gliomas. Primary outcomes included overall survival (OS), progression-free survival (PFS), feasibility, and adverse events. Study quality was assessed using Joanna Briggs Institute tools. Prospero registration: CRD420251232650. Results: Forty-one studies were included, ranging from randomized trials to case series and abstracts, utilizing interventions such as the classic 4:1 ketogenic diet, Modified Atkins Diet, and calorie restriction. Adherence was high (> 75% maintained nutritional ketosis). Recent data indicate significant survival benefits; adherent cohorts achieved a median OS of 29.4 months vs 14.6 months in historical controls; with 66.7% 3-year survival rate. The diet was well-tolerated, with adverse events limited to mild gastrointestinal symptoms and fatigue. No Grade 3/4 diet-related toxicities reported. Conclusion: Current evidence supports the KD as a safe, feasible, and biologically rational adjunct to standard glioblastoma treatment. It demonstrates potential to prolong survival without severe toxicity, highlighting the need for standardized Phase III trials to establish clinical guidelines.

Circadian rhythm disruption has emerged as a significant yet underexplored factor contributing to cancer initiation, progression, and therapeutic resistance. The circadian clock regulates approximately 40% of the human genome, orchestrating immune function, metabolism, and cellular repair. Aberrant expression of clock genes alters tumor metabolism and immune surveillance, promoting tumor growth and immune evasion. Understanding the role of circadian misalignment in cancer biology could pave the way for optimizing drug delivery, improving immune checkpoint therapy outcomes, and advancing personalized chronotherapeutic interventions.

The risk of re-occlusion and inadequate reperfusion limits the efficacy of intravenous thrombolysis (IVT) within 4.5 h for acute ischemic stroke (